 OUTLINE: This is a multicenter, phase I, dose-escalation study of temsirolimus followed by a phase II study. Patients are stratified according to study phase I vs II, histology at study enrollment glioblastoma multiforme or gliosarcoma vs anaplastic glioma, preoperative candidacy yes vs no, and presence of measurable or evaluable disease yes vs no. 